Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
biotech IPO
Biotech
Aktis aims for $209M windfall from 1st biotech IPO of 2026
Aktis Oncology is aiming to bring in $182 million—or more—from what looks set to be the first biotech IPO of 2026.
James Waldron
Jan 5, 2026 9:30am
Big Pharma-backed Aktis plans IPO to fund radiopharma trials
Dec 22, 2025 8:55am
Lumexa Imaging IPO tallies $462.5M, doubling original target
Dec 15, 2025 9:40am
Global uncertainties can't dampen upbeat Jefferies conference
Nov 24, 2025 3:00am
Inflammation biotech Evommune heads to NYSE with $150M IPO
Nov 6, 2025 7:00am
Evommune prices IPO amid government shutdown
Oct 30, 2025 12:34pm
